Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 101–150 of 75303
Effective July 7, 2026, the following directors resigned from the Board of Directors (the “Board”) of Four Leaf Acquisition Corporation (the “Company”): ● Alvin Wang ● Stephen Markscheid ● Rahul Mewawalla
Effective July 7, 2026, Ms. Coco Kou, Chief Financial Officer of the Company resigned from her position with the Company, effective immediately.
Effective as of July 7, 2026, each of Nanuk Warman, Jay Izso and Mark DiSabato was appointed as independent director to the Company’s Board of Directors.
Effective July 7, 2026, the following directors resigned from the Board of Directors (the “Board”) of Four Leaf Acquisition Corporation (the “Company”): ● Alvin Wang ● Stephen Markscheid ● Rahul Mewawalla
Effective as of July 7, 2026, each of Nanuk Warman, Jay Izso and Mark DiSabato was appointed as independent director to the Company’s Board of Directors.
Effective as of July 7, 2026, each of Nanuk Warman, Jay Izso and Mark DiSabato was appointed as independent director to the Company’s Board of Directors.
On July 2, 2026, Carson Heagen, the Chief Operating Officer of Expion360 Inc. (the “Company”), notified the board of directors of the Company that he is resigning from his role as Chief Operating Officer, effective August 1, 2026, due to personal reasons.
Jerome T. Upton, the Company’s current Executive Vice President and Chief Financial Officer (Principal Financial Officer), has been appointed Interim President and Chief Executive Officer (Principal Executive Officer), effective July 7, 2026.
Thomas J. McInerney, President & Chief Executive Officer, will be taking a temporary leave of absence from his role to focus on his health.
On July 6, 2026, Shawn Morris resigned from his position as a member of the Board of Directors (the “Board”) of Privia Health Group, Inc. (the “Company”) and as a member of the Compliance Committee of the Board, effective immediately.
On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately.
On July 7, 2026, the Board appointed David Zaccardelli, Pharm.D. to the vacancy created by Dr. Levin’s resignation, to serve on the Board as an independent Class II director until the Company’s 2029 annual meeting of stockholders and until his successor is duly elected and qualified or his earlier resignation or removal.
On June 30, 2026, the Board of Directors of Farmers & Merchants Bancorp, Inc. (the “Company”) determined to appoint Gregory R. Allen to fill an open vacancy on its Board of Directors.
On June 30, 2026, Michael D. Hill, Chief Financial Officer of Upland Software, Inc. (the “Company”) notified the board of directors of the Company (the “Board”) of his intention to retire as Chief Financial Officer, effective July 27, 2026 (the “Effective Date”).
On July 6, 2026, the Board appointed David Tamez to serve as the interim Chief Financial Officer of the Company, effective as of the Effective Date, until a permanent successor is identified.
Lori M. Toomey, a member of the Board of Directors (the “Board”) of Kingfish Holding Corporation (the “Company”), has advised the Company on June 30, 2026, that she has determined not to stand for re-election at the Company’s 2027 annual meeting of shareholders.
Additionally , effective as of June 26, 2026 , the Manager promoted Jason Slutsky , previously the General Counsel of the Manager , to Chief Operating Officer and General Counsel .
Eff e cti v e June 26 , 2026, Brian Douglas , previously the Chief Executive Officer of Graham Capital Management , L.P., the manag e r (the "Manager") of Graham Alternative Investment Fund I LLC (the "Company"), retired from his role at the Manager.
Effective June 26, 2026, Brian Douglas, previously the Chief Executive Officer of Graham Capital Management, L.P., the manager (the "Manager") of Graham Alternative Investment Fund II LLC (the "Company"), retired from his role at the Manager.
Additionally, effective as of June 26, 2026, the Manager promoted Jason Slutsky, previously the General Counsel of the Manager, to Chief Operating Officer and General Counsel.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, Amanda Baldwin, John Duffy, Melisa Gill, and Martijn de Regt were appointed as directors of the Company.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, Amanda Baldwin, John Duffy, Melisa Gill, and Martijn de Regt were appointed as directors of the Company.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, Amanda Baldwin, John Duffy, Melisa Gill, and Martijn de Regt were appointed as directors of the Company.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, Amanda Baldwin, John Duffy, Melisa Gill, and Martijn de Regt were appointed as directors of the Company.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
Mr. Charles W. Ergen will take over Mr. Akhavan’s responsibilities as Principal Executive Officer of Hughes.
Mr. Hamid Akhavan, Chief Executive Officer, EchoStar Capital, President and Chief Executive Officer Hughes (as defined below) and a member of EchoStar Corporation’s (“EchoStar” or the “Company”) and Hughes Satellite Systems Corporation (“Hughes”) boards of directors, notified the Company and Hughes that he will resign effective immediately from all positions with the Company and Hughes.
Jonathan M. Pfohl, who currently serves as the Company’s Interim Chief Executive Officer and Chief Financial Officer, was appointed to serve as a member of the Board.
David M. Garrity was appointed as an independent member of the Board to hold office until the next annual meeting of stockholders and until his successor is duly elected and qualified.
the Board of Directors (the “Board”) of Digimarc Corporation (the “Company”) previously appointed Paul Carreiro as President and Chief Executive Officer of the Company, effective July 6, 2026
Aitan Zacharin resigned from all officer positions effective immediately upon such appointment and agreed to remain as a member of the Board of Directors solely until the expiration of the ten (10) day period required under Rule 14f-1.
On June 29, 2026, Porfirio Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the Board, and a member of the Board of Directors of the Company.
Upon expiration of such period, Mr. Zacharin’s resignation as a director will become effective and Mr. Sanchez Talavera will remain as the sole director of the Company.
As previously announced, on June 7, 2026, the Board appointed Albert A. Manzone as the Company’s Interim President and Chief Executive Officer.
appointed John M. Lutz, 64, to the Board, filling the vacancy.
announced the retirement of Jason Phillips from the Company at the end of this year.
Steven Dorwart will succeed Mr. Phillips as President, Connectivity and Cloud Solutions, effective immediately.
On July 3, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board elected Laurie Keating to serve as a member of the Board, effective as of August 1, 2026.
On July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.
On July 1, 2026, Steven Kemps notified S&P Global Inc. (the “Company”) of his decision to retire from his role as Executive Vice President, Chief Legal Officer, effective December 31, 2026
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.